P45 In vitro fibrillar collagen assay development to enable drug discovery in fibrosis

Clicks: 1
ID: 318451
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #254 of 300 articles by views in the british journal of dermatology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 300 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Introduction and aims The extracellular matrix (ECM) is essential for maintaining tissue architecture and function. Collagens, the most abundant ECM proteins, require tightly regulated biosynthesis for tissue homeostasis. Dysregulated collagen production contributes to fibrosis and age-related tissue degeneration, leading to impaired organ function and increased morbidity. Here, we developed 2-dimensional (2D) and 3-dimensional (3D) in vitro models to quantify collagen production to validate the effect of compounds that may modulate collagen synthesis. Methods Human dermal fibroblasts (FBs) were cultured until D14 postconfluence; from D7, cells received 10 ng mL−1 transforming growth factor (TGF)-β1 to increase collagen biosynthesis. On D10, cells were transferred to serum-free media containing phosphate-buffered saline (control), ethanol (vehicle), or 0.1 mmol L–1 ethyl-3,4-dihydrobenzoate (EDHB), a prolyl 4-hydroxylase inhibitor which blocks collagen biosynthesis. Collagens type I and III were assessed by quantitative polymerase chain reaction (n = 3) and Western blot (n = 3), secreted collagen via enzyme-linked immunosorbent assay (pCOL1; n = 3) and cellular and ECM-deposited proteins by immunofluorescence (n = 3; pCOL1, COL1, pCOL3, COL3). Human skin equivalents (HSEs) (3D) were developed using FBs from either healthy or hypertrophic scar skin seeded into a rat tail collagen-derived scaffold; after 2 days, matched keratinocytes were added, constructs air-lifted and cultured for a further D14. Western blots were analysed in ImageJ normalized to Ponceau staining. (Pro)collagen types I and III were assessed via immunofluorescence (n = 3); images were processed by Otsu-thresholding. In 2D cultures, integrated intensity per image was measured. In HSEs, signals were thresholded to distinguish nuclear overlapping from ECM proteins. Data were analysed using either paired Student’s t-tests or Anova, as appropriate, with significance taken at the 95% confidence level. Results In 2D, TGF-β1 significantly upregulated collagen (P < 0.05) while EDHB treatment significantly reduced it (P < 0.05). In HSEs, collagen levels significantly increased over time in culture and were higher in constructs derived from healthy skin. Conclusions This study provides methods to assess the impact of drug treatments on collagen biosynthesis.
Reference Key
openalex_W7165692934 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Wai Theng Mak, F Rifkhana Shah Jalan, Deyvapriya Siva, R E Watson
Journal the british journal of dermatology
Year 2026
DOI
10.1093/bjd/ljag151.084
URL
https://doi.org/10.1093/bjd/ljag151.084
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.